Proteases in Patients With Prostate Cancer That Has Spread to the Bone
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899665|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : February 11, 2014
RATIONALE: Collecting and storing samples of bone marrow and tissue from patients to test in the laboratory may help the study of cancer.
PURPOSE: This laboratory study is comparing proteases (enzymes that break down protein) in patients with prostate cancer that has spread to the bone with patients who do not have cancer that has spread to the bone.
|Condition or disease||Intervention/treatment|
|Anemia Metastatic Cancer Myelodysplastic Syndromes Precancerous Condition Prostate Cancer||Genetic: fluorescence in situ hybridization Genetic: microarray analysis Genetic: molecular diagnostic method Other: immunohistochemistry staining method Other: laboratory biomarker analysis Procedure: biopsy Procedure: immunoscintigraphy|
- Examine the roles of proteases and protease-associated molecules in bone metastases in patients with metastatic prostate cancer.
OUTLINE: Patients undergo bone marrow aspiration and core bone biopsies. Tissues are analyzed by immunohistochemistry methods, in situ hybridization assays, gelatin zymography and/or Western blot analysis, and gene profiling analysis in order to visualize and quantitate protease or protease-related levels.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||31 participants|
|Official Title:||Proteases in Prostate Cancer Bone Metastasis|
|Study Start Date :||July 2001|
|Actual Primary Completion Date :||September 2006|
|Actual Study Completion Date :||January 2008|
- Expression and activity of proteases and related molecules
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899665
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48076|
|Study Chair:||Michael L. Cher, MD||Barbara Ann Karmanos Cancer Institute|